2017•Unpublished venueRequires access

Apomorphine formulation influences subcutaneous complications in continuous apomorphine pump therapy for Parkinson’s disease

Peter Hagell, Arja Höglund, Carina Hellqvist, Eva-Lena Johansson, Berit Löwed, Ann-Christine Sjöström, Carina Karlberg, Maragreth Lundgren, Nil Dizdar, Anders Johansson, Thomas Willows, Johan Rådberg, Filip Bergquist

Open publisher page 0 citations

Abstract

Objective: To explore if the occurrence and severity of subcutaneous (sc) nodules is influenced by the pharmaceutical formulation of apomorphine used for sc infusion in advanced Parkinson’s disease ...

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Apomorphine, Parkinson's disease, Medicine, Disease, Subcutaneous injection, Anesthesia, Dopaminergic, Dopamine